What is Catalyst Pharmaceuticals Inc's earnings per share (EPS)?

Catalyst Pharmaceuticals Inc (CPRX) reported diluted earnings per share of $1.68 for fiscal year 2025. This represents a 28.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Catalyst Pharmaceuticals Inc Financials

CPRX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Catalyst Pharmaceuticals Inc (CPRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 24 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 88/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

100

Catalyst Pharmaceuticals Inc has an operating margin of 43.8%, meaning the company retains $44 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from 39.7% the prior year.

Growth

Catalyst Pharmaceuticals Inc's revenue surged 19.8% year-over-year to $589.0M, reflecting rapid business expansion. This strong growth earns a score of 66/100.

Leverage

Catalyst Pharmaceuticals Inc carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.08, Catalyst Pharmaceuticals Inc holds $6.08 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

100

Catalyst Pharmaceuticals Inc converts 35.4% of revenue into free cash flow ($208.6M). This strong cash generation earns a score of 100/100.

Returns

Catalyst Pharmaceuticals Inc's ROE of 22.5% shows moderate profitability relative to equity, earning a score of 61/100. This is up from 22.5% the prior year.

Altman Z-Score Safe

14.80

Catalyst Pharmaceuticals Inc scores 14.80, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.0B) relative to total liabilities ($149.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

4/9

Catalyst Pharmaceuticals Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Mixed

0.97x

For every $1 of reported earnings, Catalyst Pharmaceuticals Inc generates $0.97 in operating cash flow ($208.7M OCF vs $214.3M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$589.0M

YoY+19.8%

5Y CAGR+37.7%

Catalyst Pharmaceuticals Inc generated $589.0M in revenue in fiscal year 2025. This represents an increase of 19.8% from the prior year.

EBITDA

$295.7M

YoY+26.9%

5Y CAGR+48.2%

Catalyst Pharmaceuticals Inc's EBITDA was $295.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26.9% from the prior year.

Net Income

$214.3M

YoY+30.8%

5Y CAGR+23.4%

Catalyst Pharmaceuticals Inc reported $214.3M in net income in fiscal year 2025. This represents an increase of 30.8% from the prior year.

EPS (Diluted)

$1.68

YoY+28.2%

5Y CAGR+18.8%

Catalyst Pharmaceuticals Inc earned $1.68 per diluted share (EPS) in fiscal year 2025. This represents an increase of 28.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$208.6M

YoY-12.8%

5Y CAGR+35.9%

Catalyst Pharmaceuticals Inc generated $208.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 12.8% from the prior year.

Cash & Debt

$709.2M

YoY+37.0%

5Y CAGR+40.3%

10Y CAGR+38.0%

Catalyst Pharmaceuticals Inc held $709.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

123M

YoY+1.4%

5Y CAGR+3.4%

10Y CAGR+4.0%

Catalyst Pharmaceuticals Inc had 123M shares outstanding in fiscal year 2025. This represents an increase of 1.4% from the prior year.

Margins & Returns

Gross Margin

85.2%

YoY-0.8pp

5Y CAGR-0.5pp

Catalyst Pharmaceuticals Inc's gross margin was 85.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.8 percentage points from the prior year.

Operating Margin

43.8%

YoY+4.1pp

5Y CAGR+9.1pp

Catalyst Pharmaceuticals Inc's operating margin was 43.8% in fiscal year 2025, reflecting core business profitability. This is up 4.1 percentage points from the prior year.

Net Margin

36.4%

YoY+3.1pp

5Y CAGR-26.6pp

Catalyst Pharmaceuticals Inc's net profit margin was 36.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.1 percentage points from the prior year.

Return on Equity

22.5%

YoY-0.1pp

5Y CAGR-21.8pp

10Y CAGR+58.9pp

Catalyst Pharmaceuticals Inc's ROE was 22.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$12.7M

YoY+0.5%

5Y CAGR-5.1%

10Y CAGR+0.7%

Catalyst Pharmaceuticals Inc invested $12.7M in research and development in fiscal year 2025. This represents an increase of 0.5% from the prior year.

Share Buybacks

$25.3M

Catalyst Pharmaceuticals Inc spent $25.3M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$58K

YoY-89.6%

5Y CAGR+39.4%

10Y CAGR+9.5%

Catalyst Pharmaceuticals Inc invested $58K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.6% from the prior year.

CPRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$589.0M+19.8%	$491.7M+23.5%	$398.2M+85.9%	$214.2M+52.1%	$140.8M+18.3%	$119.1M
Cost of Revenue	$87.3M+26.7%	$68.8M+32.5%	$52.0M+51.1%	$34.4M+57.2%	$21.9M+28.4%	$17.0M
Gross Profit	$501.7M+18.6%	$422.9M+22.1%	$346.2M+92.6%	$179.8M+51.2%	$118.9M+16.6%	$102.0M
R&D Expenses	$12.7M+0.5%	$12.6M-86.4%	$93.2M+370.7%	$19.8M+16.8%	$16.9M+2.7%	$16.5M
SG&A Expenses	$193.8M+9.0%	$177.7M+32.9%	$133.7M+134.2%	$57.1M+15.0%	$49.6M+12.2%	$44.2M
Operating Income	$257.8M+32.1%	$195.1M+124.8%	$86.8M-14.8%	$101.8M+94.4%	$52.4M+26.8%	$41.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$69.2M+32.1%	$52.4M+126.7%	$23.1M+6.8%	$21.6M+64.1%	$13.2M+139.8%	-$33.1M
Net Income	$214.3M+30.8%	$163.9M+129.5%	$71.4M-14.0%	$83.1M+110.4%	$39.5M-47.3%	$75.0M
EPS (Diluted)	$1.68+28.2%	$1.31+107.9%	$0.63-16.0%	$0.75+102.7%	$0.37-47.9%	$0.71

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$152.6M+2.8%	$148.4M+1.2%	$146.6M+3.6%	$141.4M-0.3%	$141.8M+10.2%	$128.7M+4.9%	$122.7M+24.6%	$98.5M
Cost of Revenue	$26.1M+15.1%	$22.7M+9.9%	$20.6M+15.1%	$17.9M-17.2%	$21.6M+12.3%	$19.3M+25.1%	$15.4M+23.0%	$12.5M
Gross Profit	$126.5M+0.6%	$125.7M-0.2%	$125.9M+2.0%	$123.5M+2.8%	$120.2M+9.8%	$109.4M+2.0%	$107.3M+24.8%	$86.0M
R&D Expenses	$1.8M-32.0%	$2.7M-39.0%	$4.4M+12.1%	$3.9M+2.3%	$3.8M+15.7%	$3.3M+10.0%	$3.0M+15.7%	$2.6M
SG&A Expenses	$53.4M+12.5%	$47.5M+3.3%	$45.9M-2.1%	$46.9M+6.2%	$44.2M-3.7%	$45.9M+12.6%	$40.7M-13.2%	$46.9M
Operating Income	$61.8M-6.7%	$66.3M0.0%	$66.3M+4.6%	$63.4M+0.8%	$62.8M+23.4%	$50.9M-6.2%	$54.2M+100.0%	$27.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$19.2M+5.2%	$18.3M+6.2%	$17.2M+18.1%	$14.5M-20.3%	$18.2M+37.0%	$13.3M-11.2%	$15.0M+157.9%	$5.8M
Net Income	$52.7M-0.2%	$52.8M+1.3%	$52.1M-8.2%	$56.7M+1.4%	$55.9M+27.5%	$43.9M+7.6%	$40.8M+75.3%	$23.3M
EPS (Diluted)	N/A	$0.42+2.4%	$0.41-8.9%	$0.45	N/A	$0.35+6.1%	$0.33+73.7%	$0.19

CPRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.1B+29.7%	$851.4M+81.1%	$470.1M+25.2%	$375.6M+58.0%	$237.8M+23.6%	$192.4M
Current Assets	$894.0M+43.4%	$623.6M+184.3%	$219.3M-31.6%	$320.8M+52.7%	$210.1M+31.9%	$159.2M
Cash & Equivalents	$709.2M+37.0%	$517.6M+276.0%	$137.6M-53.9%	$298.4M+74.0%	$171.4M+31.6%	$130.2M
Inventory	$37.2M+90.2%	$19.5M+24.9%	$15.6M+129.9%	$6.8M-13.5%	$7.9M+69.2%	$4.7M
Accounts Receivable	$126.5M+93.2%	$65.5M+22.4%	$53.5M+412.6%	$10.4M+57.7%	$6.6M+10.6%	$6.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$149.7M+21.0%	$123.8M+50.5%	$82.2M+9.3%	$75.2M+142.9%	$31.0M+36.0%	$22.8M
Current Liabilities	$147.2M+21.9%	$120.7M+58.7%	$76.1M+32.1%	$57.6M+112.8%	$27.1M+18.9%	$22.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$954.3M+31.1%	$727.6M+87.6%	$387.9M+29.1%	$300.4M+45.2%	$206.8M+22.0%	$169.6M
Retained Earnings	$474.2M+66.3%	$285.2M+135.1%	$121.3M+143.2%	$49.9M+289.5%	-$26.3M+51.0%	-$53.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.1B+5.0%	$1.1B+8.2%	$971.9M+6.9%	$908.9M+6.7%	$851.4M+10.3%	$772.0M+9.3%	$706.4M+9.2%	$646.7M
Current Assets	$894.0M+4.9%	$852.5M+12.4%	$758.7M+10.6%	$685.7M+10.0%	$623.6M+15.7%	$539.0M+13.6%	$474.4M+17.3%	$404.6M
Cash & Equivalents	$709.2M+2.8%	$689.9M+5.7%	$652.8M+12.4%	$580.7M+12.2%	$517.6M+17.0%	$442.3M+17.7%	$375.7M+21.0%	$310.4M
Inventory	$37.2M+32.6%	$28.0M+50.3%	$18.6M-5.7%	$19.8M+1.2%	$19.5M-2.4%	$20.0M+11.1%	$18.0M-9.7%	$20.0M
Accounts Receivable	$126.5M+18.9%	$106.4M+61.6%	$65.9M-7.6%	$71.3M+8.8%	$65.5M+12.4%	$58.3M+1.9%	$57.2M-5.5%	$60.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$149.7M+14.0%	$131.4M+13.3%	$115.9M+1.1%	$114.6M-7.4%	$123.8M+11.4%	$111.1M+13.7%	$97.7M+14.6%	$85.3M
Current Liabilities	$147.2M+14.3%	$128.7M+13.9%	$113.0M+1.2%	$111.6M-7.5%	$120.7M+14.5%	$105.4M+14.2%	$92.3M+16.0%	$79.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$954.3M+3.7%	$920.2M+7.5%	$856.0M+7.8%	$794.3M+9.2%	$727.6M+10.1%	$660.9M+8.6%	$608.7M+8.4%	$561.4M
Retained Earnings	$474.2M+6.1%	$446.8M+13.4%	$394.0M+15.2%	$341.9M+19.9%	$285.2M+24.4%	$229.2M+23.7%	$185.3M+28.2%	$144.5M

CPRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$208.7M-13.0%	$239.8M+67.0%	$143.6M+23.7%	$116.0M+92.2%	$60.4M+34.1%	$45.0M
Capital Expenditures	$58K-89.6%	$556K+140.7%	$231K+696.6%	$29K-97.2%	$1.0M+9181.8%	$11K
Free Cash Flow	$208.6M-12.8%	$239.3M+66.9%	$143.4M+23.6%	$116.0M+95.5%	$59.4M+31.8%	$45.0M
Investing Cash Flow	-$58K+89.6%	-$556K+99.8%	-$293.5M-3287.1%	$9.2M+183.6%	-$11.0M-119.9%	-$5.0M
Financing Cash Flow	-$17.0M-112.1%	$140.7M+1395.6%	-$10.9M-740.9%	$1.7M+120.8%	-$8.1M-1260.0%	$702K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$25.3M	$0	$0-100.0%	$6.9M-42.9%	$12.1M	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$44.9M+38.4%	$32.4M-54.5%	$71.3M+18.7%	$60.0M-15.3%	$70.9M-2.7%	$72.9M+13.6%	$64.1M+100.9%	$31.9M
Capital Expenditures	$32K	$0-100.0%	$26K	$0-100.0%	$88K-66.0%	$259K+2490.0%	$10K-95.0%	$199K
Free Cash Flow	$44.9M+38.3%	$32.4M-54.5%	$71.3M+18.7%	$60.0M-15.2%	$70.8M-2.5%	$72.6M+13.2%	$64.1M+102.1%	$31.7M
Investing Cash Flow	-$32K	$0+100.0%	-$26K	$0+100.0%	-$88K+66.0%	-$259K-2490.0%	-$10K+95.0%	-$199K
Financing Cash Flow	-$25.6M-649.6%	$4.7M+433.7%	$872K-71.5%	$3.1M-31.0%	$4.4M+174.2%	-$6.0M-616.3%	$1.2M-99.2%	$141.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CPRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	85.2%-0.8pp	86.0%-1.0pp	87.0%+3.0pp	83.9%-0.5pp	84.5%-1.2pp	85.7%
Operating Margin	43.8%+4.1pp	39.7%+17.9pp	21.8%-25.7pp	47.5%+10.3pp	37.2%+2.5pp	34.7%
Net Margin	36.4%+3.1pp	33.3%+15.4pp	17.9%-20.9pp	38.8%+10.8pp	28.0%-34.9pp	63.0%
Return on Equity	22.5%-0.1pp	22.5%+4.1pp	18.4%-9.2pp	27.7%+8.6pp	19.1%-25.1pp	44.2%
Return on Assets	19.4%+0.2pp	19.3%+4.1pp	15.2%-6.9pp	22.1%+5.5pp	16.6%-22.4pp	39.0%
Current Ratio	6.08+0.9	5.17+2.3	2.88-2.7	5.57-2.2	7.76+0.8	7.00
Debt-to-Equity	0.16-0.0	0.17-0.0	0.21-0.0	0.25+0.1	0.15+0.0	0.13
FCF Margin	35.4%-13.2pp	48.6%+12.7pp	36.0%-18.2pp	54.2%+12.0pp	42.1%+4.3pp	37.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	82.9%-1.8pp	84.7%-1.2pp	85.9%-1.4pp	87.3%+2.6pp	84.7%-0.3pp	85.0%-2.4pp	87.5%+0.2pp	87.3%
Operating Margin	40.5%-4.1pp	44.7%-0.6pp	45.2%+0.4pp	44.8%+0.5pp	44.3%+4.7pp	39.6%-4.6pp	44.2%+16.7pp	27.5%
Net Margin	34.5%-1.0pp	35.6%+0.0pp	35.5%-4.6pp	40.1%+0.7pp	39.4%+5.3pp	34.1%+0.9pp	33.2%+9.6pp	23.6%
Return on Equity	5.5%-0.2pp	5.7%-0.4pp	6.1%-1.1pp	7.1%-0.5pp	7.7%+1.0pp	6.6%-0.1pp	6.7%+2.6pp	4.2%
Return on Assets	4.8%-0.3pp	5.0%-0.3pp	5.4%-0.9pp	6.2%-0.3pp	6.6%+0.9pp	5.7%-0.1pp	5.8%+2.2pp	3.6%
Current Ratio	6.08-0.5	6.62-0.1	6.71+0.6	6.14+1.0	5.17+0.1	5.11-0.0	5.14+0.1	5.09
Debt-to-Equity	0.16+0.0	0.140.0	0.140.0	0.14-0.0	0.170.0	0.170.0	0.160.0	0.15
FCF Margin	29.4%+7.5pp	21.9%-26.8pp	48.6%+6.2pp	42.5%-7.5pp	49.9%-6.5pp	56.4%+4.2pp	52.3%+20.0pp	32.2%

Similar Companies

Amicus Therapeut FOLD

$4.5B

CG Oncology, Inc. CGON

$5.7B

Travere Therapeutics Inc TVTX

$2.8B

Immunitybio Inc IBRX

$7.5B

Celcuity Inc CELC

$5.4B

Frequently Asked Questions

What is Catalyst Pharmaceuticals Inc's annual revenue?

Catalyst Pharmaceuticals Inc (CPRX) reported $589.0M in total revenue for fiscal year 2025. This represents a 19.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Catalyst Pharmaceuticals Inc's revenue growing?

Catalyst Pharmaceuticals Inc (CPRX) revenue grew by 19.8% year-over-year, from $491.7M to $589.0M in fiscal year 2025.

Is Catalyst Pharmaceuticals Inc profitable?

Yes, Catalyst Pharmaceuticals Inc (CPRX) reported a net income of $214.3M in fiscal year 2025, with a net profit margin of 36.4%.

What is Catalyst Pharmaceuticals Inc's EBITDA?

Catalyst Pharmaceuticals Inc (CPRX) had EBITDA of $295.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Catalyst Pharmaceuticals Inc's gross margin?

Catalyst Pharmaceuticals Inc (CPRX) had a gross margin of 85.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Catalyst Pharmaceuticals Inc's operating margin?

Catalyst Pharmaceuticals Inc (CPRX) had an operating margin of 43.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Catalyst Pharmaceuticals Inc's net profit margin?

Catalyst Pharmaceuticals Inc (CPRX) had a net profit margin of 36.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Catalyst Pharmaceuticals Inc's return on equity (ROE)?

Catalyst Pharmaceuticals Inc (CPRX) has a return on equity of 22.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Catalyst Pharmaceuticals Inc's free cash flow?

Catalyst Pharmaceuticals Inc (CPRX) generated $208.6M in free cash flow during fiscal year 2025. This represents a -12.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Catalyst Pharmaceuticals Inc's operating cash flow?

Catalyst Pharmaceuticals Inc (CPRX) generated $208.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Catalyst Pharmaceuticals Inc's total assets?

Catalyst Pharmaceuticals Inc (CPRX) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Catalyst Pharmaceuticals Inc's capital expenditures?

Catalyst Pharmaceuticals Inc (CPRX) invested $58K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Catalyst Pharmaceuticals Inc spend on research and development?

Catalyst Pharmaceuticals Inc (CPRX) invested $12.7M in research and development during fiscal year 2025.

Does Catalyst Pharmaceuticals Inc buy back shares?

Yes, Catalyst Pharmaceuticals Inc (CPRX) spent $25.3M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Catalyst Pharmaceuticals Inc have outstanding?

Catalyst Pharmaceuticals Inc (CPRX) had 123M shares outstanding as of fiscal year 2025.

What is Catalyst Pharmaceuticals Inc's current ratio?

Catalyst Pharmaceuticals Inc (CPRX) had a current ratio of 6.08 as of fiscal year 2025, which is generally considered healthy.

What is Catalyst Pharmaceuticals Inc's debt-to-equity ratio?

Catalyst Pharmaceuticals Inc (CPRX) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Catalyst Pharmaceuticals Inc's return on assets (ROA)?

Catalyst Pharmaceuticals Inc (CPRX) had a return on assets of 19.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Catalyst Pharmaceuticals Inc's Altman Z-Score?

Catalyst Pharmaceuticals Inc (CPRX) has an Altman Z-Score of 14.80, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Catalyst Pharmaceuticals Inc's Piotroski F-Score?

Catalyst Pharmaceuticals Inc (CPRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Catalyst Pharmaceuticals Inc's earnings high quality?

Catalyst Pharmaceuticals Inc (CPRX) has an earnings quality ratio of 0.97x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Catalyst Pharmaceuticals Inc?

Catalyst Pharmaceuticals Inc (CPRX) scores 88 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.